Rasch-Transformed Total Neuropathy Score clinical version (RT-TNSc©) in patients with chemotherapy-induced peripheral neuropathy

Journal of the Peripheral Nervous System

Volumn 20, Issue 3, 2015, Pages 328-332

  Binda, Davide ^a   Cavaletti, Guido ^a   Cornblath, David R ^b   Merkies, Ingemar S J ^c,d  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^d Department of Orthopaedic Surgery   (Netherlands)

Author keywords

chemotherapy; peripheral neuropathy; psychometrics; Rasch analysis; total neuropathy score

Indexed keywords

ADULT; AGED; ARTICLE; CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY; CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CULTURAL FACTOR; DEEP TENDON REFLEX; FEMALE; HUMAN; ITALY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MOTOR DYSFUNCTION ASSESSMENT; MULTICENTER STUDY; MUSCLE STRENGTH; OUTCOME ASSESSMENT; PERIPHERAL NEUROPATHY; PINPRICK TEST; PRIORITY JOURNAL; PSYCHOMETRY; RASCH ANALYSIS; RASCH TRANSFORMED TOTAL NEUROPATHY SCORE CLINICAL VERSION; RELIABILITY; SENSATION; TENDON REFLEX; VALIDITY; VIBRATION; ADVERSE DRUG REACTION; AGE; CHEMICALLY INDUCED; COMPLICATION; DISABILITY; PATHOPHYSIOLOGY; QUALITY OF LIFE; RETROSPECTIVE STUDY; SEVERITY OF ILLNESS INDEX;

AGE FACTORS; DISABILITY EVALUATION; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HUMANS; MALE; PERIPHERAL NERVOUS SYSTEM DISEASES; QUALITY OF LIFE; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX;

EID: 84942586213     PISSN: 10859489     EISSN: 15298027     Source Type: Journal    
DOI: 10.1111/jns.12140     Document Type: Article

References (30)

1. Andrich D, Lyne A, Sheridan B, Luo G, (2010). RUMM 2030. RUMM Laboratory, Perth.
2. Bland JM, Altman DG, (1995). Multiple significance tests: the Bonferroni method. BMJ 310: 170.
3. Cavaletti G, Frigeni B, Lanzani F, Mattavelli L, Susani E, Alberti P, Cortinovis D, Bidoli P, (2010). Chemotherapy-induced peripheral neurotoxicity assessment: a critical revision of the currently available tools. Eur J Cancer 46: 479-494.
4. Cavaletti G, Cornblath DR, Merkies IS, Postma TJ, Rossi E, Frigeni B, Alberti P, Bruna J, Velasco R, Argyriou AA, Kalofonos HP, Psimaras D, Ricard D, Pace A, Galie E, Briani C, Dalla Torre C, Faber CG, Lalisang RI, Boogerd W, Brandsma D, Koeppen S, Hense J, Storey D, Kerrigan S, Schenone A, Fabbri S, Valsecchi MG, Group CI-P (2013). The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings. Ann Oncol 24: 454-462.
5. Chaudhry V, Rowinsky EK, Sartorius SE, Donehower RC, Cornblath DR, (1994). Peripheral neuropathy from taxol and cisplatin combination chemotherapy: clinical and electrophysiological studies. Ann Neurol 35: 304-311.
6. Chaudhry V, Eisenberger MA, Sinibaldi VJ, Sheikh K, Griffin JW, Cornblath DR, (1996). A prospective study of suramin-induced peripheral neuropathy. Brain 119: 2039-2052.
7. Cornblath DR, Chaudhry V, Carter K, Lee D, Seysedadr M, Miernicki M, Joh T, (1999). Total neuropathy score. Neurology 53: 1660-1664.
8. Draak THP, Vanhoutte EK, van Nes SI, Gorson KC, Van der Pol WL, Notermans NC, Nobile-Orazio E, Léger JM, Van den Bergh PYK, Lauria G, Bril V, Katzberg H, Lunn MPT, Pouget J, van der Kooi AJ, Hahn AF, Doorn PA, Cornblath DR, van den Berg LH, Faber CG, Merkies ISJ, (2014). Changing outcome in inflammatory neuropathies: Rasch-comparative responsiveness. Neurology 83: 2124-2132.
9. Fisher WP, (1992). Reliability statistics. Rasch Measure Transac 6: 238.
10. Gilchrist LS, Tanner L, (2013). The pediatric-modified total neuropathy score: a reliable and valid measure of chemotherapy-induced peripheral neuropathy in children with non-CNS cancers. Support Care Cancer 21: 847-856.
11. Grimby G, Tennant A, Tesio L, (2012). The use of raw scores from ordinal scales: time to end malpractice? J Rehabil Med 44: 97-98.
12. Hermans MC, Faber CG, De Baets MH, de Die-Smulders CE, Merkies IS, (2010). Rasch-built myotonic dystrophy type 1 activity and participation scale (DM1-Activ). Neuromuscul Disord 20: 310-318.
13. Hobart J, Cano S, (2009). Improving the evaluation of therapeutic interventions in multiple sclerosis: the role of new psychometric methods. Health Technol Assess 13: 1-177.
14. Hobart J, Cano S, Zajicek JP, Thompson AJ, (2007). Rating scales as outcome measures for clinical trials in neurology: problems, solutions, and recommendations. Lancet Neurol 6: 1094-1105.
15. Kucukdeveci AA, Sahin H, Ataman S, Griffiths B, Tennant A, (2004). Issues in cross-cultural validity: example from the adaptation, reliability, and validity testing of a Turkish version of the Stanford Health Assessment Questionnaire. Arthritis Rheum 51: 14-19.
16. Martina IS, van Koningsveld R, Schmitz PI, van der Meche FG, van Doorn PA, (1998). Measuring vibration threshold with a graduated tuning fork in normal aging and in patients with polyneuropathy. European Inflammatory Neuropathy Cause and Treatment (INCAT) group. J Neurol Neurosurg Psychiatry 65: 743-747.
17. Merkies IS, Schmitz PI, van der Meche FG, van Doorn PA, The Inflammatory Neuropathy Cause and Treatment (INCAT) Group (2000). Reliability and responsiveness of a graduated tuning fork in immune mediated polyneuropathies. J Neurol Neurosurg Psychiatry 68: 669-671.
18. Murphy SM, Herrmann DN, McDermott MP, Scherer SS, Shy ME, Reilly MM, Pareyson D, (2011). Reliability of the CMT neuropathy score (second version) in Charcot-Marie-Tooth disease. J Peripher Nerv Syst 16: 191-198.
19. Pallant JF, Tennant A, (2007). An introduction to the Rasch measurement model: an example using the Hospital Anxiety and Depression Scale (HADS). Br J Clin Psychol 46: 1-18.
20. Rasch G, (1960). Probabilistic Models for Some Intelligence and Attainment Tests. University of Chicago Press, Chicago.
21. Rowinsky EK, Gilbert MR, McGuire WP, Noe DA, Grochow LB, Forastiere AA, Ettinger DS, Lubejko BG, Clark B, Sartorius SE, (1991). Sequences of taxol and cisplatin: a phase I and pharmacologic study. J Clin Oncol 9: 1692-1703.
22. Rowinsky EK, Chaudhry V, Forastiere AA, Sartorius SE, Ettinger DS, Grochow LB, Lubejko BG, Cornblath DR, Donehower RC, (1993). Phase I and pharmacologic study of paclitaxel and cisplatin with granulocyte colony-stimulating factor: neuromuscular toxicity is dose-limiting. J Clin Oncol 11: 2010-2020.
23. Shy ME, Blake J, Krajewski K, Fuerst DR, Laura M, Hahn AF, Li J, Lewis RA, Reilly M, (2005). Reliability and validity of the CMT neuropathy score as a measure of disability. Neurology 64: 1209-1214.
24. Stevens S, (1946). On the Theory of Scales of Measurement. Science 103: 677-680.
25. Streiner GR, Norman DL, (1995). Health Measurement Scales. A Practical Guide to Their Development and Use. Oxford University Press, New York.
26. Stucki G, Daltroy L, Katz JN, Johannesson M, Liang MH, (1996). Interpretation of change scores in ordinal clinical scales and health status measures: the whole may not equal the sum of the parts. J Clin Epidemiol 49: 711-717.
27. Tennant A, Conaghan PG, (2007). The Rasch measurement model in rheumatology: What is it and why use it? When should it be applied, and what should one look for in a Rasch paper? Arthritis Care Res 57: 1358-1362.
28. Vanhoutte EK, Faber CG, van Nes SI, Jacobs BC, van Doorn PA, van Koningsveld R, Cornblath DR, van der Kooi AJ, Cats EA, van den Berg LH, Notermans NC, van der Pol WL, Hermans MC, van der Beek NA, Gorson KC, Eurelings M, Engelsman J, Boot H, Meijer RJ, Lauria G, Tennant A, Merkies IS, PeriNom SSG, (2012). Modifying the Medical Research Council grading system through Rasch analyses. Brain 135: 1639-1649.
29. Vanhoutte EK, Faber CG, Merkies ISJ, (2013). 196th ENMC international workshop: Outcome measures in inflammatory peripheral neuropathies 8-10 February 2013, Naarden, The Netherlands. Neuromuscul Disord 23: 924-933.
30. Wright BD, Stone MH, (1979). Best Test Design. Mesa Press, Chicago.